896 1030
[12]
Mendhiratta N, Rosenkrantz AB, Meng X, et al. MRI-ultrasound fusion-targeted prostate biopsy in a consecutive cohort of men with no previous biopsy: reduction of over-detection through improved risk stratification. J Urol 2015;194:1601–6.[13]
Meng X, Rosenkrantz AB, Mendhiratta N, et al. Relationship be- tween prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion–targeted prostate biopsy outcomes. Eur Urol 2016;69:512–7.
[14]
Vargas HA, Ho¨tker AM, Goldman DA, et al. Updated Prostate Imaging Reporting and Data System (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol 2016;26:1606–12.[15]
Radtke JP, Kuru TH, Boxler S, et al. Comparative analysis of trans- perineal template saturation prostate biopsy versus magnetic res- onance imaging targeted biopsy with magnetic resonance imaging- ultrasound fusion guidance. J Urol 2015;193:87–94.
[16]
Roobol MJ, van Vugt HA, Loeb S, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012;61:577–83.
[17]
Moore CM, Kasivisvanathan V, Eggener S, et al. Standards of report- ing for MRI-targeted biopsy studies (START) of the prostate: recom- mendations from an international working group. Eur Urol 2013;64:544–52.
[18]
Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008;8:53.
[19] Gerds TA. ModelGood: validation of risk prediction models. R pack-
age version 1.0.9.
https://CRAN.R-project.org/package=ModelGood2014.
[20] Harrell Jr F. rms: Regression Modeling Strategies. R package version
5.1-0.
https://CRAN.R-project.org/package=rms2017.
[21]
Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and, accurate reporting of studies of diagnostic accuracy: the STARD initiative. Radiology 2003;226:24–8.
[22]
Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening?. A meta- analysis. Ann Oncol 2015;26:848–64.
[23]
van Vugt HA, Roobol MJ, Kranse R, et al. Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur J Cancer 2011;47:903–9.
[24]
Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol MJ. Risk-based patient selection for magnetic resonance imaging-targeted prostate biopsy after negative transrectal ultrasound-guided random biopsy avoids unnecessary magnetic resonance imaging scans. Eur Urol 2016;69:1129–34.
[25]
Poyet C, Nieboer D, Bhindi B, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Pre- vention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary Europe. BJU Int 2015;117: 401–8.
[26]
Renard-Penna R, Mozer P, Cornud F, et al. Prostate Imaging Report- ing and Data System and Likert scoring system: multiparametric MR imaging validation study to screen patients for initial biopsy. Radiology 2015;275:458–68.
[27]
Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of Prostate Imaging Reporting and Data System Version 2 for detec- tion of prostate cancer: a systematic review and diagnostic meta- analysis. Eur Urol 2017;72:177–88.
[28]
Auer T, Edlinger M, Bektic J, et al. Performance of PI-RADS version 1 versus version 2 regarding the relation with histopathological results. World J Urol 2017;35:687–93.
[29]
Rosenkrantz AB, Ginocchio LA, Cornfeld D, et al. Interobserver repro- ducibility of the PI-RADS Version 2 Lexicon: a multicenter study of six experienced prostate radiologists. Radiology 2016;280:793–804.
[30]
De Rooij M, Crienen S, Witjes JA, Barentsz JO, Rovers MM, Grutters JPC. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultra- sound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur Urol 2014;66:430–6.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 8 8 – 8 9 6
896